2012•Int J ImmunolRequires access

The research progression of immunotherapy for metastatic renal cell carcinoma

Liwei Liwei, Quanli Gao

Abstract

Metastatic renal cell carcinoma (RCC) usually resistants to traditional chemotherapy and radiotherapy.Interleukin-2 and interferon-αare the common significant cytokines studied extensively.However the clinical efficacy is not desirable when interleukin-2 or interferon-αis used alone.With the development of molecular immunology,studies on vaccines and autologous cytokine induced killer Cells progress quickly.This review summarizes the research progression of immunotherapy for metastatic renal cell carcinoma. Key words: Metastatic renal cell carcinoma; Immunotherapy

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Immunotherapy, Renal cell carcinoma, Medicine, Cytokine, Cancer research, Chemotherapy, Carcinoma, Interleukin 2